EGL-001 + anti-pd(l)-1 inhibitor

This is a **combination therapy** under clinical investigation, composed of EGL-001, a Treg-selective anti-CTLA4-IL-2 mutant (fusion protein), administered together with an anti-PD(L)-1 inhibitor. EGL-001 antagonizes the CTLA-4-CD80/86 interaction and selectively depletes regulatory T cells (Tregs) within the tumor microenvironment by downregulating CD25 and inhibiting IL-2 signaling in these cells. The combination is designed to enhance anti-tumor immune responses by both depleting immunosuppressive Tregs (via EGL-001) and blocking the PD-1/PD-L1 axis (via the anti-PD(L)-1 inhibitor), leveraging complementary checkpoint inhibition. This strategy is being evaluated in phase I/II clinical trials in adult patients with advanced or metastatic solid tumors, particularly those who have previously been treated with immune checkpoint inhibitors and experienced secondary resistance[1][2][3][4][6].